This site is currently implementing core features and is not ready for patient use yet.
This site is currently implementing core features and is not ready for patient use yet.
For informational purposes only — not medical advice
How serious?
Risk of death
Yes
Vaccine available?
Time to symptoms
Countries affected
Active outbreaks
Included in the MMR vaccine — verify 2 doses before travel. Risk is low for fully vaccinated travelers. Outbreaks occur in close-contact settings (dormitories, ships). If you develop swollen salivary glands with fever, seek medical evaluation.
Viral infection primarily affecting the salivary glands, causing painful facial swelling. Largely prevented by MMR vaccination.
Viral infection primarily affecting the salivary glands.
Mumps is caused by the Mumps paramyxovirus spread via respiratory droplets and direct contact with saliva. The hallmark is parotid gland swelling. Once common in childhood, it is now rare in countries with high MMR vaccine coverage, though outbreaks occur in close-contact settings.
Seek urgent medical care if:
Sudden severe testicular pain or swelling (orchitis)
Severe headache, stiff neck, or sensitivity to light (meningitis)
Severe abdominal pain (pancreatitis)
Sudden hearing loss
High fever (>39.5°C) not responding to antipyretics
Altered consciousness or seizures
Most common signs and symptoms
Prodromal phase (1–2 days): Low-grade fever, headache, malaise, and muscle aches.
Active phase (up to 10 days): Painful swelling of one or both parotid glands (parotitis), causing "chipmunk cheek" appearance. Swelling peaks 2–3 days after onset. Earache when chewing. Fever 38–39°C.
Up to 20% of infections are asymptomatic. Orchitis (testicular inflammation) develops in 20–50% of post-pubertal males after parotitis onset, presenting with sudden testicular pain and swelling.
Knowing the symptoms is the first step to a quick response.
Typical disease course:
Asymptomatic infection: 20–30% of mumps infections are subclinical. Another 40–50% present with nonspecific respiratory symptoms only.
How this disease is identified
Clinical diagnosis is confirmed by parotid swelling in an unvaccinated individual with epidemiological exposure. Laboratory confirmation:
Serology: IgM antibody detection (positive 5 days after symptom onset)
RT-PCR from buccal swab or urine — most sensitive within first 5 days
Viral culture: reference laboratories Consider mumps in any vaccinated individual with parotitis during an outbreak.
Available treatment methods
No specific antiviral therapy. Supportive management:
Analgesics (paracetamol/ibuprofen) for pain and fever
Warm or cold compresses over swollen glands for comfort
Adequate hydration; soft, easy-to-chew foods
Orchitis: scrotal support, bed rest, analgesics; corticosteroids in severe cases
Viral meningitis: supportive care with monitoring
Isolation for 5 days after parotid swelling onset to prevent transmission
Most cases are effectively treated with early diagnosis.
How to protect yourself
Two-dose MMR vaccine provides approximately 88% protection against mumps:
Dose 1: 12–15 months of age
Dose 2: 4–6 years of age
Third dose considered during outbreaks in vaccinated populations
No post-exposure prophylaxis (immunoglobulin not effective for mumps) Close contacts in outbreak settings should receive a third MMR dose if two prior doses were received more than 3 years ago.
Preparation is the best protection.
Ensure 2 doses of MMR before travel to regions with active outbreaks.
Risk is elevated in settings with close contact: camps, pilgrimages (Hajj), universities.
Mumps is reportable in most countries — inform local health authorities of suspected cases.
Travelers in outbreak areas may benefit from a third MMR dose if their last dose was >3 years ago.
Statistics and geographic data
Before vaccination, mumps was endemic worldwide with peak incidence in children 5–9 years. The MMR vaccine reduced incidence by >99% in high-coverage countries. Outbreaks continue in vaccinated populations in close-contact settings (universities, military, sports teams), suggesting waning immunity. Europe and North America have documented resurgence since 2005. Immunity from 2-dose MMR wanes over 10–15 years.
Who is most at risk
Risk factors for mumps infection:
Vaccination status: Unvaccinated or incompletely vaccinated individuals have the highest risk. However, waning immunity means that even two-dose MMR recipients become increasingly susceptible over time (particularly >10 years after the second dose).
Close-contact settings: University dormitories, military barracks, boarding schools, prisons, and sports teams create ideal conditions for transmission. Most contemporary outbreaks in vaccinated populations occur in these settings.
Age: In the prevaccine era, peak incidence was in children aged 5–9 years. In the vaccine era, outbreaks have shifted to young adults (18–25 years), reflecting waning immunity from childhood vaccination.
Travel: Exposure to regions with endemic mumps or ongoing outbreaks, particularly areas with low MMR coverage.
Crowding and shared living spaces: Household secondary attack rate in susceptible contacts is 40–50%.
Risk factors for complications:
Post-pubertal age: Orchitis occurs almost exclusively in post-pubertal males (15–30% of post-pubertal male mumps cases vs. <1% in prepubertal boys). Oophoritis occurs in 5% of post-pubertal females.
Age >15 years: Meningitis and encephalitis are more common in adolescents and adults than in young children.
Male sex: Males are 3–5 times more likely to develop mumps encephalitis than females.
Immunosuppression: Limited data, but immunocompromised individuals may have atypical presentations and prolonged viral shedding.
Genotype: Some evidence suggests that genotype G (currently dominant globally) may be associated with higher rates of complications in vaccinated populations, possibly due to antigenic differences from the Jeryl Lynn vaccine strain (genotype A), though this remains debated.
Potential complications
Orchitis: 20–50% of post-pubertal males
rarely causes infertility (~13% of bilateral cases)
Oophoritis: 5% of post-pubertal females
rarely affects fertility
Viral meningitis: 1–10% of cases
usually self-limiting with complete recovery
Encephalitis: rare (<2/100,000)
can cause long-term neurological sequelae
Pancreatitis: mild, self-limiting, <4% of cases
Sensorineural hearing loss: rare, may be permanent
associated with labyrinthitis
Myocarditis: very rare
electrocardiographic changes in ~15% of mumps cases without clinical symptoms
Expected outcomes and recovery
Overall: Excellent prognosis. CFR ~0.01%. Self-limiting in the vast majority.
Complications:
Orchitis (testicular inflammation): 15–30% of post-pubertal males. Bilateral in 15–30% of orchitis cases. Subfertility is rare (<5%); complete sterility is extremely rare.
Oophoritis: 5% of post-pubertal females.
Aseptic meningitis: 1–10% (usually benign, resolves in 3–10 days).
Sensorineural deafness: 1 in 20,000 (usually unilateral, may be permanent).
Pancreatitis: 4% (usually mild, self-limiting).
Immunity: Lifelong after natural infection. Vaccine-induced immunity may wane (secondary vaccine failure contributing to outbreaks in vaccinated populations).
This disease is vaccine-preventable. Effective protection is available through vaccination.
Talk to a travel health specialist about the recommended schedule before your trip.
Find a vaccination clinic →The content on this page is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. If you have health concerns, consult a qualified healthcare professional. Medova is not a medical service provider.
Full terms of useRecent epidemiological data from the World Health Organization Global Health Observatory.
Source: WHO GHO OData ↗
And 15 more records
This data is provided for informational purposes. Please consult official WHO sources for the most current information.
View WHO data source →Know which vaccine you need? Great. Not sure? Just tell us your destination — we will figure it out and match you with a clinic. Free, no obligation.